ArticleMikrochimica acta2026
Zein-templated synthesis of Au@Pt bimetallic nanozymes: a multi-mode lateral flow immunoassay platform for ultrasensitive colorimetric and fluorometric detection of tetracycline in food.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The systematic development of a multifunctional zein-stabilized Au@Pt bimetallic nanozyme (zein-Au@Pt) for highly efficient multimodal detection of tetracycline (TC) is described. We created a core-shell nanostructure using zein protein as a biomimetic template, combining the Au@Pt bimetallic interface's high peroxidase-mimicking activity with the prolamine shell's fluorescence. Zein-Au@Pt exhibited low Michaelis constants (𝐾𝑚 for H₂O₂: 0.813 mM; TMB: 0.211 mM) in steady-state kinetics, indicating high substrate affinity. A multimodal lateral flow immunoassay (LFIA) platform allows traditional colorimetric screening, catalytically amplified detection, and fluorescence measurement. These three approaches had detection limits of 0.9, 0.09, and 0.014 ng/mL, respectively, demonstrating 10-fold (catalytic amplification) and 64-fold (fluorescence sensitization) increases in sensitivity over traditional colorimetric LFIA. High recoveries (89.8-109.3%) across various complex animal-derived matrices demonstrated its adaptability as a multimodal LFIA platform for on-site screening after minimal sample preprocessing for antibiotic residue surveillance. Despite these benefits, challenges remain, including potential cross-reactivity with TC analogs in complex matrices, the need to miniaturize the fluorescence readout device for true point-of-care use, and the long-term stability of the zein protein coating under different storage conditions. Engineering highly specialized recognition elements (aptamers) to overcome cross-reactivity, integrating smartphone-based detecting systems for mobility, and scaling up zein-templated nanozymes for commercial use are future priorities.
Indexed as
Identifiers
42825836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.